US20050171590A1 - Cardiomyopathy treatment device with electrode therapy - Google Patents

Cardiomyopathy treatment device with electrode therapy Download PDF

Info

Publication number
US20050171590A1
US20050171590A1 US11/098,327 US9832705A US2005171590A1 US 20050171590 A1 US20050171590 A1 US 20050171590A1 US 9832705 A US9832705 A US 9832705A US 2005171590 A1 US2005171590 A1 US 2005171590A1
Authority
US
United States
Prior art keywords
heart
sack
ventricles
electrodes
leads
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/098,327
Inventor
Yuzi Okuzumi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acorn Cardiovascular Inc
Original Assignee
Acorn Cardiovascular Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorn Cardiovascular Inc filed Critical Acorn Cardiovascular Inc
Priority to US11/098,327 priority Critical patent/US20050171590A1/en
Publication of US20050171590A1 publication Critical patent/US20050171590A1/en
Priority to US12/767,302 priority patent/US20100222636A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0587Epicardial electrode systems; Endocardial electrodes piercing the pericardium

Definitions

  • This invention relates to a biocompatible, biostable and implantable heart sack which is prepared from biocompatible, biostable and implantable elastomers selected from the group consisting of polyetherurethane, polycarbonateurethane, silicone, poly(siloxane) urethane and/or hydrogenated poly (styrene-butadiene) copolymer for the treatment of cardiomyopathy, hypertrophic cardiomyopathy, tachycardia, bradycardia, ventricular fibrillation, atrial fibrillation etc.
  • biocompatible, biostable and implantable elastomers selected from the group consisting of polyetherurethane, polycarbonateurethane, silicone, poly(siloxane) urethane and/or hydrogenated poly (styrene-butadiene) copolymer for the treatment of cardiomyopathy, hypertrophic cardiomyopathy, tachycardia, bradycardia, ventricular fibrillation, atrial fibrillation etc.
  • the heart sack of this invention can be reinforced with mono-filaments, yarns, braids, cords, knitted or woven or non-woven cloth made of a biocompatible, biostable, implantable polyamide, polyimide, polyester, polypropylene, and/or polyurethane etc.
  • the heart sack of this invention can be equipped with pacemaker leads and defibrillation leads.
  • the leads and electrodes of this invention are made of noble metal or stainless steel deposited, coated or plated mono-filaments, yarns, braids, cords, wires, films, cloth and/or cylindrical tubes.
  • the noble metal used for this invention is selected from the group consisting of gold, platinum, rhodium and their alloys.
  • the mono-filaments, yarns, braids, cords, wires, films, cloth or cylindrical tubes materials to be coated, deposited or plated with noble metal are selected from the group consisting of poly(ethylene terephthalate), poly(butylene terephthalate), polyamide, polyimide, polypropylene, polyetherurethane, polycarbonateurethane and their copolymers.
  • the heart sack and electrodes are very flexible and have good biocompliance with heart muscle. They have high strength and excellent mechanical properties. Ordinary pacemaker leads and defibrillation leads could be also imbedded into the heart sack to provide cardiac pacing or defibrillation.
  • Cardiomyopathy is a commonly observed disease in an aging population. Cardiomyopathy is a defect of myocardial function. There are three categories of Cardiomyopathies; dilated cardiomyopathy, hypertrophic cardiomyopathy and restrictive cardiomyopathy. Dilated cardiomyopathy refers to a condition in which there is weakened contraction of the ventricles with an apparent dilation of the ventricles. This leads to inadequate perfusion, and increased pulmonary and systemic venous congestion. It will lead essentially to loss of heart function. The history of the disease is one of to progressive deterioration. The mortality in one year is greater than 50% for those people who have a poorly functioning heart. Hyper cardiomyopathy is a disease of the heart muscle.
  • Restrictive cardiomyopathy is least common of cardiomyopathies. It is due to other pathological processes such as scerderma, amyloid, sarcoid, or storage decease. This invention is to prevent enlargement of the heart and thinning of the heart wall of patients with dilated cardiomyopathy, or hypertrophic cardiomyopathy by the use of a heart sack.
  • the implantable heart sack of this invention was prepared from a biocompatible, biostable and implantable elastomer selected from the group consisting of polyetherurethane, polycarbonateurethane, silicone, polysiloxaneurethane and/or hydrogenated poly (styrene-butadiene) copolymer. Grooves can be made on the inside of the sack to accommodate blood vessels and pacing or defibrillation leads. Holes can be punched out from the heart sack to accommodate the pulmonary artery and aorta.
  • the heart sack can be made to be a semipermeable membrane by providing numerous micro holes in the heart sack.
  • the heart sack of this invention can be reinforced with mono-filaments, yarns, braids, cords, knitted, woven and/or non-woven cloth made of a biostable, implantable polyamide, polyimide, polyester, polypropylene, or polyurethane etc.
  • the heart sack is split from the upper edge of the sack through the pulmonary artery and aorta openings. In this way, the sack can be opened to fit onto the heart.
  • Several sutures are attached on one side or both sides of the cutting.
  • the pacemaker leads and/or electrode of this invention are made of noble metal or stainless steel coated, deposited or plated mono-filaments, yarns, braids, cords, wires, films, cloth cylindrical tubes, and laminated films. These articles are encased in multi-lumen insulating tubing having at least two lumens or in layers of the coaxial insulation tubes.
  • the materials chosen for the implantable heart sack of this invention were selected from the group consisting of polyetherurethane, polycarbonateurethane, silicone, poly(siloxane) urethane, ethylene-propylene and dieyclopentadiene terpolymer, and/or hydrogenated poly (styrene-butadiene) copolymer. These polymers were chosen due to their elasticity, excellent biostability and biocompatibility.
  • the heart sack can be prepared from casting, coating, extruding, molding of these biocompatible and biostable materials.
  • the preferred polyurethane is selected from the group consisting of poly(tetramethylene-ether glycol) urethanes and poly(hexamethylenecrbonate-ethylenecarbonate glycol) urethanes such as Dow Chemical Company PellethaneTM 90A, and PellethaneTM 55D.
  • the preferred polycarbonateurethane is Polymer Technology Inc BionateTM or Thermedics Inc CarbothaneTM.
  • the preferred silicone rubber has durometer hardness range of between 30 to 85. Both peroxide cure silicone and platinum cured silicone can be used.
  • Examples are the Dow Corning Inc medical grade 70000 series, Q-4865 and Q-6860 series silicone, NuSil Inc MED 4535, 4550, 4560, 4750, 4770, and 4780 series silicone, and equivalent products of other manufacturers.
  • the preferred polysiloxaneurethane is Elastomedics Elast-EonTM.
  • the heart sack made from these polymers possesses excellent long-term biostability, good biocompatibility, no toxicity and good resistance to the environmental stress cracking.
  • a heart sack can be reinforced with high strength fibers or filaments of polyamide, polyimide, polyester, and polypropylene or crosslinked polyurethane.
  • the preferred reinforcing material is poly(ethylene terephthalate), and poly(butylene terephthalate).
  • the filaments and cords prepared from these polymer have very high tensile strength and have good long-term biostability when imbedded in the aforementioned biocompatible and biostable elastomers.
  • Contoured grooves can be made on the inside of the heart sack to accommodate blood vessels and pacing or defibrillation leads by designing dies for the casting or molding.
  • the heart sack is split from the upper edge of the sack through the pulmonary artery, aorta and other blood vessel openings. In this way, the sack can be opened to fit onto the heart.
  • Sutures are attached on one side or both sides of the cutting. Suturing enable to tie the heart sack tightly onto the heart.
  • Pacing and defibrillation leads of this invention comprises the noble metal coated, deposited, or plated mono-filaments, yarns, braids, cords, wires, films, cloth or cylindrical tubes, and laminated films that are encased in multi-lumen insulating sleeves or coaxial tubes.
  • the metal coated, deposited or plated articles can be prepared by vacuum coating, vacuum deposition, chemical or physical deposition, spattering, chemical or electric reductions of the metallic ions or chemical plating etc.
  • Noble metals such as gold, iridium, platinum, rhodium and their alloys or corrosion resistant stainless steel can be coated, deposited or plated onto fibers and films to form an electric conductive electrode and leads elements.
  • these metal coated, deposited or plated products are referred as “noble metal coated” products.
  • the noble metal coated mono-filaments, yarns, braids, cords, wires films, cloth or cylindrical tubes and laminated films etc. must have excellent electric conductivity, biostability and biocompatibility.
  • Noble metals which meet these requirements, due to their very low electric resistance, and excellent biostability and biocompatibility, are gold, platinum, rhodium and platinum-rhodium alloy.
  • Preferred metals are platinum and platinum rhodium alloys. Platinum has an extremely low electric resistance of 0.000275 ohm per meter. Biostability, to biocompatibility, and low electric resistance of platinum and platinum-rhodium alloys are extensively proven as the pacemaker and defibrillator electrodes.
  • the mono-filaments, yarns, braids, cords, wires, films, cloth or cylindrical tubes, and laminated films of this invention to be coated, deposited or plated with noble metal need to have high strength, good biocompatibility and long term biostability.
  • these mono-filaments, yarns, braids, cords, wires, films, cloth or cylindrical tubes, and laminated films may be referred as “fiber and film” products.
  • Polymers, which meet these requirements, are poly(ethylene terephthalate), poly(butylene terephthalate), polyamide, polyimide, polypropylene, polyurethane, and their copolymers.
  • the preferred material to make fiber, filament yarn and film is poly(ethylene terephthalate) (PET). PET has an excellent physical strength, good biocompatibility, biostability, and is already utilized in construction of artificial heart valves, and artificial blood vessels.
  • the highly electric conductive noble metal coated articles described above are encased in multi-lumen insulating tubing having at least two lumens or encased in coaxial tubing.
  • the elastomers which have excellent insulating properties and which meet requirements for implantation are polyetherurethane, polycarbonateurethane, silicone, polysiloxaneurethane, polyfluoroethylene, or hydrogenated poly(styrene-butadiene) copolymer and the same as described in the above heart sack materials. Tubes made from these polymers are known to have an excellent long-term biostability, good biocompatibility, no toxicity and good resistance to the environmental stress cracking.
  • a multi-lumen tube of at least three lumens is preferred for the bipolar leads.
  • the coaxial leads can be fabricated from alternating layers of the aforementioned insulating tubing and an electrically conductive material made of the noble metal coated mono-filaments, yarns, braids, cords, wires, films, cloth or cylindrical tubes.
  • a special alloy MP35N coil also can be used as the leads electric conductor.
  • the leads are fabricated in to such a way that one end of the leads or cable can be connected to a pacemaker or defibrillator.
  • the noble metal coated fibers and/or films protrude from another end of the multi-lumen leads or coaxial leads for a designated length.
  • the insulation material is made of one or more of the aforementioned biocompatible, biostable and implantable insulating polymer and has one or more grooves.
  • the electrodes are bonded into grooves in parallel in a designated width, or the electrode is attached individually on the separate insulation material. Multiple grooves can be made to accommodate multiple electrodes.
  • the insulation sheet that has grooves can be extruded using a film die with appropriate shape. To mount the noble metal coated fiber electrode into the groove, a round groove having the diameter slightly smaller to slightly larger than that of the fiber with 1/32 to 1 ⁇ 2 of the circumference opened or cut away is preferred.
  • the electrode can be retained in the grooves and leaves 1/32 to 1 ⁇ 2 of the metal-coated fiber surface exposed on the surface of the insulating sheet.
  • rectangular grooves can be made in an insulating sheet to accommodate the metal coated film electrodes.
  • the noble metal coated films can be laminated with one or more of the aforementioned biocompatible, biostable and implantable elastomer sheet in parallel in a designated width from each other, or individually bonded onto the separate insulation material to make electrodes.
  • the electrode and insulating ribbons can be heat treated and annealed to contour the heart sack. This assures tight contact with the heart muscle.
  • the pacemaker leads are fabricated in such a way that one end of the leads can be connected to an implanted pacemaker or defibrillator.
  • the noble metal coated electric conductive elements protruded from another end of the leads can be also connected to the regular pacemaker electrodes and defibrillator electrodes.
  • MP35N coil or silver /MP35N coil is used as electric conductive material for the leads
  • a portion of the protruding MP35N coil can be connected to the ribbons or strips of metal coated fibers and bonded onto the insulation materials in the same manner described above.
  • the connection area can be sealed with polyurethane, silicone or epoxy resin sealant to prevent short-circuiting and abrasion.
  • the leads can be imbedded directly in the heart sack or inserted into the groove in the heart sack.
  • the self-contouring and flexible electrodes provide excellent to mechanical and physiological compliance to prevent mechanically induced damages such as thickened epineurium, increased subperineural and endoneural connective tissue, endoneural edima, demmyelinization, or axonal degeneration.
  • An ordinary pacemaker leads and defibrillation leads can be also imbedded or inserted into the groove in the heart sack to treat tachycardia, bradycardia, ventricular fibrillation, atrial fibrillation etc.
  • the ribbons or strips of the noble metal coated films that are laminated with the aforementioned implantable elastomer can be inserted or mounted onto separate areas of the inner side of the heart sack to provide for the proper pacing or defibrillation for the separate heart chamber.
  • the film electrode, ribbon, fiber electrode and heart sack can be heated treated to shrink or form a contoured configuration to fit exactly onto the heart, so that the electrodes make tight contact with the heart wall.
  • the whole heart sack can be made semipermeable or totally permeable depending upon the hear sack size and physiological requirements.
  • the semipermeable membrane can be prepared from a molding mixture of polymers with a designated molecular weight and proportion of leaching component. Pore size and porosity is proportional to the molecular weight and amount of leaching compound. Leaching out the soluble component from an injection molded heart sack creates a semipermeable membrane. A phase inversion casting method can be also used. Micro or macro holes can be also mechanically perforated in the heart sack. This will allow body fluid to freely flow around the heart sack. The number and size of holes can be optimized depend upon the size of heart sack and physiological requirements.
  • the heart sack and noble metal coated leads materials have excellent biocompliance with the heart muscle. Further reduction in the coefficient of friction can be achieved by the use of a hydrophilic coating applied onto the leads and electrode insulation surface.
  • the whole heart sack and leads assemblies, except the electrode surface, can be coated with a thin layer of a biocompatible, hydrophilic coating to lower coefficient of friction.
  • This type of coating was prepared from the polyvinylpyrrolidone (PVP)-polyurethane interpenetrating polymer.
  • the coating solution was prepared from dissolving polyvinylpyrrolidone and urethane into organic solvents.
  • a hydrophilic coating also can be made by depositing a solid polyvinylpyrrolidone derivative onto the heart sack.
  • the PVP coating provides excellent biocompatibility and low coefficient of friction when wet with blood or body fluid. The coating swells in water but will not dissolve or leach out and is extremely hydrophilic.
  • An incidence of infection associated with the implantation of medical devices in the body is often life threatening. Some particularly persistent infectious organisms are staphylococcus, staphylococcus epidermis, and pseudomonas auerignosa. Staphylococcus is especially dangerous because it has an affinity for plastics. Enterooccus is another gram-positive organism that causes life-threatening infection and is resistant to a broad range of antibiotics.
  • the incidence of infection associated with the implanted medical devices can be prevented with the use of antimicrobial agents. Coating, impregnation and compounding of antimicrobial agents on medical devices can prevent infection associated with the implant operation.
  • Antimicrobial agents which are suited for this purpose, are benzalkoniumchloride (BAC), chlorhexidine dihydrochloride (CHD), dodecarbonium chloride (DCC), and silver sufadiazine (SSD).
  • BAC benzalkoniumchloride
  • CHD chlorhexidine dihydrochloride
  • DCC dodecarbonium chloride
  • SSD silver sufadiazine
  • the amount of antimicrobial agent required depends upon the agent. It generally ranges from 0.0001% to 0.5%.
  • BAC, DCC and SSD can be dissolved or dispersed in coating.
  • These antimicrobial agents can be added to the biocompatible, lubricious and hydrophilic coating described in above.
  • Anti microbial agents can also be added to a bioresorbable polymer solution of polyglycolide, polylactide or collagen. Medical devices can then be coated with this antimicrobial solution.
  • CHD due to its high decomposition temperature and good thermal stability can be compounded into polyurethane and silicone polymers and then extruded to form tubing, sheet and other shaped articles.
  • These methods of antimicrobial coating, impregnation of the antimicrobial agents, or compounding of the antimicrobial agents into the insulation materials can be applied to any other type of heart sack, leads and electrodes.
  • a heart shaped polypropylene model including all blood vessel components was coated with a 10% solution of Pellethane 90AE in N-dimethylpyrrolidone and dried. The process was repeated three times to obtain an adequate coating thickness. Then, a screen made of poly(ethylene terephthalate) (PET) was placed onto the coated model and coated again with the Pellethane solution. Coating and drying were repeated several times. Then, the heart shaped skin was removed from the model by making a slit from the center upper edge to below the aorta to obtain a heart shaped sack. Then, a number of polypropylene sutures were attached on the both side of the slit. The sutures make it easier to dose the slit and secure the heart sack on the heart.
  • PET poly(ethylene terephthalate)
  • a heart shaped polypropylene model including all blood vessel components was coated with a polyurethane solution prepared from polytetramethylene ether glycol having a molecular weight of 1,000, methylene bis-phenylisocyanate, and ethylenediamine in dimethylacetoamide and dried. The process was repeated two times to obtain an adequate coating thickness. Then, a screen made of poly(ethylene terephthalate) (PET) was placed onto the coated model and coated again with the Pellethane solution. Coating and drying were repeated several times. Then, the heart shaped skin was removed from the model by making a slit from the center upper edge to below the aorta to obtain a heart shaped sack. Then, a number of polypropylene sutures were attached on the both side of the slit. The sutures make it easier to dose the slit and secure the heart sack on the heart.
  • a polyurethane solution prepared from polytetramethylene ether glycol having a molecular weight of 1,000
  • Poly(ethylene terephthalate) monofilament having a 20 micron diameter was plated with approximately 0.5 micron thick platinum.
  • a yarn consisting of 48 platinum deposited monofilament was braided to make an electrically conductive wire.
  • the braid having a 60 mm length and 1.8 mm diameter had an electric resistance of 0.7 ohms.
  • a platinum coated fiber braid 800 mm long and 0.6 mm in diameter had a tresistance of 35 ohms.
  • the product had extremely good corrosion resistance. No corrosion was found after 400 ⁇ 15 amp 0.10 milli-second defibrillation shocks in 0.9% saline.
  • the platinum-coated fiber had very low toxicity and passed both the ASTM F813 Cytotoxicity Assay and the Cell Growth Inhibition-Cytotoxicity Assay.
  • Two braids of platinum deposited poly(ethylene terephthalate) fibers having 0.6 mm dia were inserted into two lumen Pellethane tubing.
  • the braids protruding from one end of the tubing were connected to the adapters that fit into a pacemaker.
  • the braids protruding from the other end of the tube were bonded into a groove in the inner surface of the heart sack in such way that the electrodes are exposed on the inner surface of the heart sack.
  • the heart sack was placed on the polypropylene heart model and annealed at 85° C. for two hours. After cooling hear sack equipped with the electrode and leads contoured with the heart sack was obtained.
  • MP 35N coils were placed in tubing (2.4 mm dia, 0.2 mm wall thickness) made of Pellethane 55D, Pellethane 80A, and peroxide cured silicone. Then, the tubing was bent in a U-shape and placed separately in 1-in diameter test tubes containing 10% peroxide solution. A braid made of platinum coated PET was also bent in the same u-shape and placed in a test tube containing 10% peroxide solution.
  • Pellethane 55D which is manufactured by Dow Chemical and which is known as a biostable and biocompatible polyurethane and Pellethane 80A which is known to be susceptible to the environmental stress cracking under mechanical stress were used as positive and negative controls.
  • Test tubes were covered by waxed plastic film and placed in an incubator at 37° C. After 6 weeks of incubation, the tubes and braids were examined under microscope. Micro-cracks were observed in the bent area of the Pellethane 80A tube. No cracks or fissures were observed on either the Pellethane SSD or the silicone and platinum coated PET.
  • Polytetramethylene ether urethane was prepared from methylene diphenyl isocyanate (MDI), poly(tetramethylene ether) glycol (PEU), and butanediol. Films (2 mm ⁇ 10 mm ⁇ 0.5 mm) were extruded from the PEU. The same size films were also extruded from polycarbonateurethane (PCU) prepared from MDI and poly(hexamethylene carbonate-ethylene carbonate) glycol (PCU), and poly(ethylene terephthalate) (PET). Platinum coated poly(ethylene terephthalate) (Pt-PET) film, and PET film coated with polyvinylpyrrolidone interpolymer (Pt-PVP) were also obtained.
  • PCU polycarbonateurethane
  • PCU poly(hexamethylene carbonate-ethylene carbonate) glycol
  • PET poly(ethylene terephthalate)
  • a semipermeable heart sack was obtained by coating and drying a heart shaped model with appropriate blood vessel features and have holes and grooves for the pacemaker leads or defibirillation leads or both, with a mixture of polyethylene glycol (PEG) having 600 molecular weight with the elastomer solution prepared from the reaction of polytetramethylene ether glycol having a molecular weight of 1,000 and methylene bis(p-phenylisocyanate) with the molar ratio of 1 to 1.6 to 1.9 respectively in N,N′dimethylacetoamide (DMA) at 85° C., then adding a mixture of ethylene diamine, 1,3 diaminocyclohexane and diethylamine in DMA (1:0.24:0.19 molar ratio respectively) to chain extend to obtaine approximately 30% solution, and adding 0.025% each of 4,4′ buttylidene-bis (6-t-butyl m-cresol) and 2 diethyaminoethy methacrylate-n-de
  • the product was placed in a 45° C. water bath to leach out the water soluble PEG.
  • the porosity and pour size of the products were controlled by the molecular weight, amount of PEG and leaching temperature.
  • heart sacks were removed from the mold making slits.
  • polypropylene sutures with needle were attached on both side of the slits. The suture enabled to secure the heart sack on the heart model and demonstrated convenience of the built-in suture.
  • the inner and outer surfaces of polyurethane heart sacks of example 8 were coated with a PVP urethane interpolymer solution.
  • the coating solution was prepared dissolving 1.5 percent weight PVP having 30 K value that is related to molecular weight of PVP, 0.5 percent weight of an adduct of methylene bis-cyclohexyl isocyanate and poly(tetraethylene ether) glycol having 1000 molecular weight, 0.3% isocyanate terminated caster oil and 0.005% stannous octoate catalyst in the mixture of solvents consisting of 35% methyl ethyl ketone, 20% ethyl lactate, 10% ethyl acetate, and 35% trichloroethylene.
  • the coating was dried in an oven at 50° C. for 2 hours.
  • a coated test sheet of polyurethane sheet prepared in the same manner demonstrated a high degree of lubricity when wet and had about one quarter the friction of Teflon.
  • a piece of polyvinylpyrrolidone-urethane coated heart sack material (2 cm diameter) was immersed in saline solutions containing 0.1% benzalkoniumchloride (BAC) and then dried. The pierce was placed on a culture dish containing staphylococcus epidermis and incubated at 37° C. for 3 days. A more than 5 mm of zone of inhibition was observed in the culture dish.
  • the polyvinylpyrrolidone-urethane coated electrodes immersed in saline solutions containing 0.1% of chlorhexidine dihydrochloride (CHD) and dodecarbonium chloride (DCC) showed more than 5 mm of zone of inhibition.
  • CHD chlorhexidine dihydrochloride
  • DCC dodecarbonium chloride

Abstract

This invention relates to implantable heart sack that can be equipped with pacemaker leads and/or defibrillation leads for the treatment of cardiomyopathy, hypertrophic cardiomyopathy tachycardia, bradycardia, ventricular fibrillation, atrial fibrillation etc. The hear sack was prepared from biocompatible, biostable, implantable polyetherurethane, polycarbonateurethane, silicone, polysiloxaneurethane, polyfluoroethylene, or hydrogenated poly(styrene-butadiene) copolymer. The heart sack is equipped with attached sutures to make it easier to attach onto the heart. The heart sack can be made semipermeable or perforated to have numerous holes. The heart sack can be reinforce with fiber or filament. Ordinary pacemaker leads can be attached to the inner side of the heart sack. However, the pacemaker leads of this invention were prepared from noble metal (gold, platinum, rhodium and platinum-Rhodium alloys) or stainless steel coated, deposited or plated mono-filaments, yarns, braids, cords, wires or films, or cylindrical tubes of polyamide, polyimide, polyester, and/or polypropylene that are encased in multi-lumen insulating tube or coaxial tube made of biocompatible, biostable, implantable polyetherurethane, polycarbonateurethane, silicone, polysiloxaneurethane, polyfluoroethylene, or hydrogenated poly(styrene-butadiene) copolymer. The leads can be mounted onto the inner surface of the heart sack and contoured to the heart. The heart sack can be coated with hydrophilic coating containing an antimicrobial agent that gives the heart sack a low coefficient of friction, excellent biocompatibility and antimicrobial properties.

Description

    FIELD OF THE INVENTION
  • This invention relates to a biocompatible, biostable and implantable heart sack which is prepared from biocompatible, biostable and implantable elastomers selected from the group consisting of polyetherurethane, polycarbonateurethane, silicone, poly(siloxane) urethane and/or hydrogenated poly (styrene-butadiene) copolymer for the treatment of cardiomyopathy, hypertrophic cardiomyopathy, tachycardia, bradycardia, ventricular fibrillation, atrial fibrillation etc. The heart sack of this invention can be reinforced with mono-filaments, yarns, braids, cords, knitted or woven or non-woven cloth made of a biocompatible, biostable, implantable polyamide, polyimide, polyester, polypropylene, and/or polyurethane etc.
  • The heart sack of this invention can be equipped with pacemaker leads and defibrillation leads. The leads and electrodes of this invention are made of noble metal or stainless steel deposited, coated or plated mono-filaments, yarns, braids, cords, wires, films, cloth and/or cylindrical tubes. The noble metal used for this invention is selected from the group consisting of gold, platinum, rhodium and their alloys. The mono-filaments, yarns, braids, cords, wires, films, cloth or cylindrical tubes materials to be coated, deposited or plated with noble metal are selected from the group consisting of poly(ethylene terephthalate), poly(butylene terephthalate), polyamide, polyimide, polypropylene, polyetherurethane, polycarbonateurethane and their copolymers. The heart sack and electrodes are very flexible and have good biocompliance with heart muscle. They have high strength and excellent mechanical properties. Ordinary pacemaker leads and defibrillation leads could be also imbedded into the heart sack to provide cardiac pacing or defibrillation.
  • REFERENCE
  • US4100309 Jul. 11, 1977 Micklus, et AL 427/002.28
    US4515593 May 7, 1985 Norton; William J 604/256
    US4573481 Jun. 25, 1984 Bullara; Leo A 607/118
    US4612337 Sep. 16, 1986 Fox, Jr; Charles L 514/038
    US4769013 Jun. 4,1986 Lorenz et Al 604/265
    US5242684 Sep. 7, 1991 Merianos; John J 424/078.07
    US5324322 Jun. 28, 1994 Grill, et Al 607/118
  • BACKGROUND OF THE INVENTION
  • Electrical therapeutic heart sack devices are a new and noble concept. Cardiomyopathy is a commonly observed disease in an aging population. Cardiomyopathy is a defect of myocardial function. There are three categories of Cardiomyopathies; dilated cardiomyopathy, hypertrophic cardiomyopathy and restrictive cardiomyopathy. Dilated cardiomyopathy refers to a condition in which there is weakened contraction of the ventricles with an apparent dilation of the ventricles. This leads to inadequate perfusion, and increased pulmonary and systemic venous congestion. It will lead essentially to loss of heart function. The history of the disease is one of to progressive deterioration. The mortality in one year is greater than 50% for those people who have a poorly functioning heart. Hyper cardiomyopathy is a disease of the heart muscle. It is characterized with an overactive left ventricle due to its increase in muscle mass resulting in an obstruction of the blood that is being pumped from the left ventricle to the rest of the body. This causes dyspnea on exertion and chest pain due to ischemia. Currently, there is no treatment to alter the course of the disease. Restrictive cardiomyopathy is least common of cardiomyopathies. It is due to other pathological processes such as scerderma, amyloid, sarcoid, or storage decease. This invention is to prevent enlargement of the heart and thinning of the heart wall of patients with dilated cardiomyopathy, or hypertrophic cardiomyopathy by the use of a heart sack.
  • BRIEF SUMMARY OF THE INVENTION
  • The implantable heart sack of this invention was prepared from a biocompatible, biostable and implantable elastomer selected from the group consisting of polyetherurethane, polycarbonateurethane, silicone, polysiloxaneurethane and/or hydrogenated poly (styrene-butadiene) copolymer. Grooves can be made on the inside of the sack to accommodate blood vessels and pacing or defibrillation leads. Holes can be punched out from the heart sack to accommodate the pulmonary artery and aorta. The heart sack can be made to be a semipermeable membrane by providing numerous micro holes in the heart sack. This can be done mechanically, or by phase inversion casting method, or leaching out a soluble blend from an injection molded heart sack. Many larger holes can be perforated in the heart sack to allow body fluid to freely flow around the heart sack. The heart sack of this invention can be reinforced with mono-filaments, yarns, braids, cords, knitted, woven and/or non-woven cloth made of a biostable, implantable polyamide, polyimide, polyester, polypropylene, or polyurethane etc. The heart sack is split from the upper edge of the sack through the pulmonary artery and aorta openings. In this way, the sack can be opened to fit onto the heart. Several sutures are attached on one side or both sides of the cutting. Suturing makes the heart sack fit tightly onto the heart. Ordinary pacemaker leads and defibrillation leads can bc imbedded into the heart sack to treat tachycardia, bradycardia, ventricular fibrillation atrial fibrillation etc. However, the ordinary pacemaker leads that interface with the exterior of the heart often lack physical and physiological compliance with the heart to muscle and its surrounding tissue resulting in mechanical abrasion and scar formation. To prevent abrasion, the pacemaker leads and/or electrode of this invention are made of noble metal or stainless steel coated, deposited or plated mono-filaments, yarns, braids, cords, wires, films, cloth cylindrical tubes, and laminated films. These articles are encased in multi-lumen insulating tubing having at least two lumens or in layers of the coaxial insulation tubes.
  • DETAILED DESCRIPTION OF THE INVENTION
  • When a man-made material is implanted in a human body, the body immediately recognizes the presence of the foreign material. This will trigger the immune defense system to eject or destroy the material and will cause edema, inflammation of the surrounding tissue, and biodegradation of the implanted material due to an enzymatic free radical attack, hydrolysis, oxidation and environmental stress cracking. Only a few polymers are known to possess a long term biostability, and good biocompatibility. The materials chosen for the implantable heart sack of this invention were selected from the group consisting of polyetherurethane, polycarbonateurethane, silicone, poly(siloxane) urethane, ethylene-propylene and dieyclopentadiene terpolymer, and/or hydrogenated poly (styrene-butadiene) copolymer. These polymers were chosen due to their elasticity, excellent biostability and biocompatibility. The heart sack can be prepared from casting, coating, extruding, molding of these biocompatible and biostable materials. The preferred polyurethane is selected from the group consisting of poly(tetramethylene-ether glycol) urethanes and poly(hexamethylenecrbonate-ethylenecarbonate glycol) urethanes such as Dow Chemical Company Pellethane™ 90A, and Pellethane™ 55D. The preferred polycarbonateurethane is Polymer Technology Inc Bionate™ or Thermedics Inc Carbothane™. The preferred silicone rubber has durometer hardness range of between 30 to 85. Both peroxide cure silicone and platinum cured silicone can be used. Examples are the Dow Corning Inc medical grade 70000 series, Q-4865 and Q-6860 series silicone, NuSil Inc MED 4535, 4550, 4560, 4750, 4770, and 4780 series silicone, and equivalent products of other manufacturers. The preferred polysiloxaneurethane is Elastomedics Elast-Eon™. The heart sack made from these polymers possesses excellent long-term biostability, good biocompatibility, no toxicity and good resistance to the environmental stress cracking. A heart sack can be reinforced with high strength fibers or filaments of polyamide, polyimide, polyester, and polypropylene or crosslinked polyurethane. The preferred reinforcing material is poly(ethylene terephthalate), and poly(butylene terephthalate). The filaments and cords prepared from these polymer have very high tensile strength and have good long-term biostability when imbedded in the aforementioned biocompatible and biostable elastomers. Contoured grooves can be made on the inside of the heart sack to accommodate blood vessels and pacing or defibrillation leads by designing dies for the casting or molding. The heart sack is split from the upper edge of the sack through the pulmonary artery, aorta and other blood vessel openings. In this way, the sack can be opened to fit onto the heart. Sutures are attached on one side or both sides of the cutting. Suturing enable to tie the heart sack tightly onto the heart.
  • The heart sack of this invention can be equipped with pacemaker leads and defibrillation leads. However, care must be taken to prevent mechanical abrasion of the heart muscle and surrounding tissues. Pacing and defibrillation leads of this invention comprises the noble metal coated, deposited, or plated mono-filaments, yarns, braids, cords, wires, films, cloth or cylindrical tubes, and laminated films that are encased in multi-lumen insulating sleeves or coaxial tubes. The metal coated, deposited or plated articles can be prepared by vacuum coating, vacuum deposition, chemical or physical deposition, spattering, chemical or electric reductions of the metallic ions or chemical plating etc. Noble metals such as gold, iridium, platinum, rhodium and their alloys or corrosion resistant stainless steel can be coated, deposited or plated onto fibers and films to form an electric conductive electrode and leads elements. Hereunder, these metal coated, deposited or plated products are referred as “noble metal coated” products.
  • To make the electrodes and leads, the noble metal coated mono-filaments, yarns, braids, cords, wires films, cloth or cylindrical tubes and laminated films etc. must have excellent electric conductivity, biostability and biocompatibility. Noble metals, which meet these requirements, due to their very low electric resistance, and excellent biostability and biocompatibility, are gold, platinum, rhodium and platinum-rhodium alloy. Preferred metals are platinum and platinum rhodium alloys. Platinum has an extremely low electric resistance of 0.000275 ohm per meter. Biostability, to biocompatibility, and low electric resistance of platinum and platinum-rhodium alloys are extensively proven as the pacemaker and defibrillator electrodes.
  • The mono-filaments, yarns, braids, cords, wires, films, cloth or cylindrical tubes, and laminated films of this invention to be coated, deposited or plated with noble metal need to have high strength, good biocompatibility and long term biostability. Hereunder, these mono-filaments, yarns, braids, cords, wires, films, cloth or cylindrical tubes, and laminated films may be referred as “fiber and film” products. Polymers, which meet these requirements, are poly(ethylene terephthalate), poly(butylene terephthalate), polyamide, polyimide, polypropylene, polyurethane, and their copolymers. The preferred material to make fiber, filament yarn and film is poly(ethylene terephthalate) (PET). PET has an excellent physical strength, good biocompatibility, biostability, and is already utilized in construction of artificial heart valves, and artificial blood vessels.
  • The highly electric conductive noble metal coated articles described above are encased in multi-lumen insulating tubing having at least two lumens or encased in coaxial tubing. The elastomers, which have excellent insulating properties and which meet requirements for implantation are polyetherurethane, polycarbonateurethane, silicone, polysiloxaneurethane, polyfluoroethylene, or hydrogenated poly(styrene-butadiene) copolymer and the same as described in the above heart sack materials. Tubes made from these polymers are known to have an excellent long-term biostability, good biocompatibility, no toxicity and good resistance to the environmental stress cracking. It is known that hydrogen peroxide simulates the oxidative actions imposed by the body against an implanted foreign material. The use of hydrogen peroxide, or hydrogen peroxide plus cobalt chloride to test biostability of materials is described in Journal of Biomaterials Research Vol. 29, 467-475 and Journal of Biomedical Material Research Vol. 27, page 327-334.
  • A multi-lumen tube of at least three lumens is preferred for the bipolar leads. The coaxial leads can be fabricated from alternating layers of the aforementioned insulating tubing and an electrically conductive material made of the noble metal coated mono-filaments, yarns, braids, cords, wires, films, cloth or cylindrical tubes. A special alloy MP35N coil also can be used as the leads electric conductor. The leads are fabricated in to such a way that one end of the leads or cable can be connected to a pacemaker or defibrillator. The noble metal coated fibers and/or films protrude from another end of the multi-lumen leads or coaxial leads for a designated length. They can be attached or bonded onto a narrow and thin strip of a insulating film, sheet or a sliced tube to form electrodes. The insulation material is made of one or more of the aforementioned biocompatible, biostable and implantable insulating polymer and has one or more grooves. The electrodes are bonded into grooves in parallel in a designated width, or the electrode is attached individually on the separate insulation material. Multiple grooves can be made to accommodate multiple electrodes. The insulation sheet that has grooves can be extruded using a film die with appropriate shape. To mount the noble metal coated fiber electrode into the groove, a round groove having the diameter slightly smaller to slightly larger than that of the fiber with 1/32 to ½ of the circumference opened or cut away is preferred. This enables the electrode to be retained in the grooves and leaves 1/32 to ½ of the metal-coated fiber surface exposed on the surface of the insulating sheet. In the same manner rectangular grooves can be made in an insulating sheet to accommodate the metal coated film electrodes. The noble metal coated films can be laminated with one or more of the aforementioned biocompatible, biostable and implantable elastomer sheet in parallel in a designated width from each other, or individually bonded onto the separate insulation material to make electrodes. The electrode and insulating ribbons can be heat treated and annealed to contour the heart sack. This assures tight contact with the heart muscle. The pacemaker leads are fabricated in such a way that one end of the leads can be connected to an implanted pacemaker or defibrillator. The noble metal coated electric conductive elements protruded from another end of the leads can be also connected to the regular pacemaker electrodes and defibrillator electrodes. When the MP35N coil or silver /MP35N coil is used as electric conductive material for the leads, a portion of the protruding MP35N coil can be connected to the ribbons or strips of metal coated fibers and bonded onto the insulation materials in the same manner described above. The connection area can be sealed with polyurethane, silicone or epoxy resin sealant to prevent short-circuiting and abrasion. The leads can be imbedded directly in the heart sack or inserted into the groove in the heart sack. The self-contouring and flexible electrodes provide excellent to mechanical and physiological compliance to prevent mechanically induced damages such as thickened epineurium, increased subperineural and endoneural connective tissue, endoneural edima, demmyelinization, or axonal degeneration. An ordinary pacemaker leads and defibrillation leads can be also imbedded or inserted into the groove in the heart sack to treat tachycardia, bradycardia, ventricular fibrillation, atrial fibrillation etc. Similarly the ribbons or strips of the noble metal coated films that are laminated with the aforementioned implantable elastomer can be inserted or mounted onto separate areas of the inner side of the heart sack to provide for the proper pacing or defibrillation for the separate heart chamber. The film electrode, ribbon, fiber electrode and heart sack can be heated treated to shrink or form a contoured configuration to fit exactly onto the heart, so that the electrodes make tight contact with the heart wall.
  • The whole heart sack can be made semipermeable or totally permeable depending upon the hear sack size and physiological requirements. The semipermeable membrane can be prepared from a molding mixture of polymers with a designated molecular weight and proportion of leaching component. Pore size and porosity is proportional to the molecular weight and amount of leaching compound. Leaching out the soluble component from an injection molded heart sack creates a semipermeable membrane. A phase inversion casting method can be also used. Micro or macro holes can be also mechanically perforated in the heart sack. This will allow body fluid to freely flow around the heart sack. The number and size of holes can be optimized depend upon the size of heart sack and physiological requirements.
  • It is desirable to eliminate the friction among the heart sack, leads and heart muscle to prevent mechanically induced damage. The heart sack and noble metal coated leads materials have excellent biocompliance with the heart muscle. Further reduction in the coefficient of friction can be achieved by the use of a hydrophilic coating applied onto the leads and electrode insulation surface. The whole heart sack and leads assemblies, except the electrode surface, can be coated with a thin layer of a biocompatible, hydrophilic coating to lower coefficient of friction. This type of coating was prepared from the polyvinylpyrrolidone (PVP)-polyurethane interpenetrating polymer. The coating solution was prepared from dissolving polyvinylpyrrolidone and urethane into organic solvents. A hydrophilic coating also can be made by depositing a solid polyvinylpyrrolidone derivative onto the heart sack. The PVP coating provides excellent biocompatibility and low coefficient of friction when wet with blood or body fluid. The coating swells in water but will not dissolve or leach out and is extremely hydrophilic.
  • An incidence of infection associated with the implantation of medical devices in the body is often life threatening. Some particularly persistent infectious organisms are staphylococcus, staphylococcus epidermis, and pseudomonas auerignosa. Staphylococcus is especially dangerous because it has an affinity for plastics. Enterooccus is another gram-positive organism that causes life-threatening infection and is resistant to a broad range of antibiotics. The incidence of infection associated with the implanted medical devices can be prevented with the use of antimicrobial agents. Coating, impregnation and compounding of antimicrobial agents on medical devices can prevent infection associated with the implant operation. Antimicrobial agents, which are suited for this purpose, are benzalkoniumchloride (BAC), chlorhexidine dihydrochloride (CHD), dodecarbonium chloride (DCC), and silver sufadiazine (SSD). The amount of antimicrobial agent required depends upon the agent. It generally ranges from 0.0001% to 0.5%. BAC, DCC and SSD can be dissolved or dispersed in coating. These antimicrobial agents can be added to the biocompatible, lubricious and hydrophilic coating described in above. Anti microbial agents can also be added to a bioresorbable polymer solution of polyglycolide, polylactide or collagen. Medical devices can then be coated with this antimicrobial solution. CHD due to its high decomposition temperature and good thermal stability can be compounded into polyurethane and silicone polymers and then extruded to form tubing, sheet and other shaped articles. These methods of antimicrobial coating, impregnation of the antimicrobial agents, or compounding of the antimicrobial agents into the insulation materials can be applied to any other type of heart sack, leads and electrodes.
  • EXAMPLE 1
  • A heart shaped polypropylene model including all blood vessel components was coated with a 10% solution of Pellethane 90AE in N-dimethylpyrrolidone and dried. The process was repeated three times to obtain an adequate coating thickness. Then, a screen made of poly(ethylene terephthalate) (PET) was placed onto the coated model and coated again with the Pellethane solution. Coating and drying were repeated several times. Then, the heart shaped skin was removed from the model by making a slit from the center upper edge to below the aorta to obtain a heart shaped sack. Then, a number of polypropylene sutures were attached on the both side of the slit. The sutures make it easier to dose the slit and secure the heart sack on the heart.
  • EXAMPLE 2
  • A heart shaped polypropylene model including all blood vessel components was coated with a polyurethane solution prepared from polytetramethylene ether glycol having a molecular weight of 1,000, methylene bis-phenylisocyanate, and ethylenediamine in dimethylacetoamide and dried. The process was repeated two times to obtain an adequate coating thickness. Then, a screen made of poly(ethylene terephthalate) (PET) was placed onto the coated model and coated again with the Pellethane solution. Coating and drying were repeated several times. Then, the heart shaped skin was removed from the model by making a slit from the center upper edge to below the aorta to obtain a heart shaped sack. Then, a number of polypropylene sutures were attached on the both side of the slit. The sutures make it easier to dose the slit and secure the heart sack on the heart.
  • EXAMPLE 3
  • To the Pellethane solution of example 1, two percent of polyethylene glycol having molecular weight of 1000 was dispersed. Then, the solution was applied to the polypropylene heart model in the same manner. The coating was dried and annealed. Thus obtained heart sack was placed in 60° C. water bath for 60 minutes to leach out the polyethylene glycol. After drying a heart sack with a semipermeable membrane was obtained.
  • EXAMPLE 4
  • Poly(ethylene terephthalate) monofilament having a 20 micron diameter was plated with approximately 0.5 micron thick platinum. A yarn consisting of 48 platinum deposited monofilament was braided to make an electrically conductive wire. The braid having a 60 mm length and 1.8 mm diameter had an electric resistance of 0.7 ohms. A platinum coated fiber braid 800 mm long and 0.6 mm in diameter had a tresistance of 35 ohms. The product had extremely good corrosion resistance. No corrosion was found after 400×15 amp 0.10 milli-second defibrillation shocks in 0.9% saline. The platinum-coated fiber had very low toxicity and passed both the ASTM F813 Cytotoxicity Assay and the Cell Growth Inhibition-Cytotoxicity Assay.
  • EXAMPLE 5
  • Two braids of platinum deposited poly(ethylene terephthalate) fibers having 0.6 mm dia were inserted into two lumen Pellethane tubing. The braids protruding from one end of the tubing were connected to the adapters that fit into a pacemaker. The braids protruding from the other end of the tube were bonded into a groove in the inner surface of the heart sack in such way that the electrodes are exposed on the inner surface of the heart sack. Then the heart sack was placed on the polypropylene heart model and annealed at 85° C. for two hours. After cooling hear sack equipped with the electrode and leads contoured with the heart sack was obtained.
  • EXAMPLE 6
  • MP 35N coils were placed in tubing (2.4 mm dia, 0.2 mm wall thickness) made of Pellethane 55D, Pellethane 80A, and peroxide cured silicone. Then, the tubing was bent in a U-shape and placed separately in 1-in diameter test tubes containing 10% peroxide solution. A braid made of platinum coated PET was also bent in the same u-shape and placed in a test tube containing 10% peroxide solution. Pellethane 55D which is manufactured by Dow Chemical and which is known as a biostable and biocompatible polyurethane and Pellethane 80A which is known to be susceptible to the environmental stress cracking under mechanical stress were used as positive and negative controls. Test tubes were covered by waxed plastic film and placed in an incubator at 37° C. After 6 weeks of incubation, the tubes and braids were examined under microscope. Micro-cracks were observed in the bent area of the Pellethane 80A tube. No cracks or fissures were observed on either the Pellethane SSD or the silicone and platinum coated PET.
  • EXAMPLE 7
  • Polytetramethylene ether urethane (PEU) was prepared from methylene diphenyl isocyanate (MDI), poly(tetramethylene ether) glycol (PEU), and butanediol. Films (2 mm×10 mm×0.5 mm) were extruded from the PEU. The same size films were also extruded from polycarbonateurethane (PCU) prepared from MDI and poly(hexamethylene carbonate-ethylene carbonate) glycol (PCU), and poly(ethylene terephthalate) (PET). Platinum coated poly(ethylene terephthalate) (Pt-PET) film, and PET film coated with polyvinylpyrrolidone interpolymer (Pt-PVP) were also obtained. All films were placed in separate vials and exposed to fresh platelet plasma concentrate. The vials were incubated at 37° C. for 30 minutes with slight agitation. Then, the films were rinsed in cold phosphate buffer and treated with 3% glutaraldehyde, dehydrated serially with increasing concentration of ethanol and air dried. Thus obtained samples were spatter coated with gold and examined using scanning electron microscope. The amounts of platelet adhesion and degree of platelet activation were measured. Round platelet and no pseudopodia present was rated 1, a few pseudopodia with no flattening was rated 2, one or more pseudopodia flattened and hyaloplasm not spread between pseudopodia was rated 3, hyaloplasm partially spread was rated 4 and hyaloplasm extensively spread were rated 5. Thus, the smaller the number the better the biocompatibility. The ratings obtained were: PEU 2, PET 4, PCU 3, Pt-PET 2, and Pt-PVP 1.
  • EXAMPLE 8
  • A semipermeable heart sack was obtained by coating and drying a heart shaped model with appropriate blood vessel features and have holes and grooves for the pacemaker leads or defibirillation leads or both, with a mixture of polyethylene glycol (PEG) having 600 molecular weight with the elastomer solution prepared from the reaction of polytetramethylene ether glycol having a molecular weight of 1,000 and methylene bis(p-phenylisocyanate) with the molar ratio of 1 to 1.6 to 1.9 respectively in N,N′dimethylacetoamide (DMA) at 85° C., then adding a mixture of ethylene diamine, 1,3 diaminocyclohexane and diethylamine in DMA (1:0.24:0.19 molar ratio respectively) to chain extend to obtaine approximately 30% solution, and adding 0.025% each of 4,4′ buttylidene-bis (6-t-butyl m-cresol) and 2 diethyaminoethy methacrylate-n-decyl methacrylate copolymer as stabilizer. After a sufficient thickness is obtained by the repeated coating and drying processes, the product was placed in a 45° C. water bath to leach out the water soluble PEG. The porosity and pour size of the products were controlled by the molecular weight, amount of PEG and leaching temperature. Thus obtained heart sacks were removed from the mold making slits. Then, polypropylene sutures with needle were attached on both side of the slits. The suture enabled to secure the heart sack on the heart model and demonstrated convenience of the built-in suture.
  • EXAMPLE 9
  • The inner and outer surfaces of polyurethane heart sacks of example 8 were coated with a PVP urethane interpolymer solution. The coating solution was prepared dissolving 1.5 percent weight PVP having 30 K value that is related to molecular weight of PVP, 0.5 percent weight of an adduct of methylene bis-cyclohexyl isocyanate and poly(tetraethylene ether) glycol having 1000 molecular weight, 0.3% isocyanate terminated caster oil and 0.005% stannous octoate catalyst in the mixture of solvents consisting of 35% methyl ethyl ketone, 20% ethyl lactate, 10% ethyl acetate, and 35% trichloroethylene. The coating was dried in an oven at 50° C. for 2 hours. A coated test sheet of polyurethane sheet prepared in the same manner demonstrated a high degree of lubricity when wet and had about one quarter the friction of Teflon.
  • EXAMPLE 10
  • A piece of polyvinylpyrrolidone-urethane coated heart sack material (2 cm diameter) was immersed in saline solutions containing 0.1% benzalkoniumchloride (BAC) and then dried. The pierce was placed on a culture dish containing staphylococcus epidermis and incubated at 37° C. for 3 days. A more than 5 mm of zone of inhibition was observed in the culture dish. Similarly, the polyvinylpyrrolidone-urethane coated electrodes immersed in saline solutions containing 0.1% of chlorhexidine dihydrochloride (CHD) and dodecarbonium chloride (DCC) showed more than 5 mm of zone of inhibition.

Claims (14)

1-20. (canceled)
21. An apparatus for treating cardiomyopathy of a heart characterized in part by dilation of ventricles of the heart, the apparatus comprising:
a device configured to completely surround at least the ventricles of a heart, said device including: a material constructed of a biocompatible material and shaped and sized to circumferentially surround the heart and covering at least the ventricles of the heart in contact with opposing tissue of said heart; and
a plurality of electrodes carried on said device and positioned to electrically contact a surface of the heart when said device is positioned on said heart with said material surrounding said ventricles; and
said electrodes adapted to be electrically connected to an electrical impulse generator.
22. An apparatus according to claim 43 further comprising an implantable electrical impulse generator operably connected to the electrodes, said impulse generator adapted to generate an electrical signal to be imparted to said heart through said electrodes.
23. An apparatus according to claim 43 wherein said material carries a pharmacologic agent.
24. An apparatus according to claim 43 wherein said material is at least partially coated with surface coating.
25. An apparatus according to claim 44 wherein said signal is a pacing signal.
26. An apparatus according to claim 44 wherein said signal is a defibrillation signal.
27. An apparatus according to claim 43 wherein said material is shaped and sized to cover an atrium of the heart.
28. An apparatus according to claim 43 wherein said material includes a plurality of holes through said material.
29. A cardiac reinforcement device, said device comprising:
a sack of biomedical material configured to completely surround at least the ventricles of a heart and prevent cardiac expansion, said sack comprising a open base end for applying said sack to the heart such that when applied the base end is oriented toward the base of the heart and said material surrounds and contacts said ventricles; and
a plurality of stimulation electrodes configured to contact the heart, whereby the sack is configured to resist dilation of the heart and the stimulation electrodes are capable of improving cardiac contraction.
30. A method for treating a disease of a heart, the method comprising:
selecting a device adapted to be placed against a surface of the heart, the device comprising a material sized and configured to surround at least the ventricles of the heart and a plurality of stimulation electrodes configured to contact the heart;
surgically placing said device on said heart with said material contacting a surface of said heart at least surrounding said ventricles and with said material circumferentially surrounding said ventricles, said placement including positioning said device with said electrodes electrically contacting said heart;
applying a therapeutic electrical signal to said electrodes.
31. A method according to claim 50 wherein said device is sized and configured to cover an atrium of said heart.
32. A method according to claim 50 wherein said therapeutic electrical signal is a pacing signal.
33. A method according to claim 50 wherein said therapeutic electrical signal is a defibrillation signal.
US11/098,327 1998-11-04 2005-04-04 Cardiomyopathy treatment device with electrode therapy Abandoned US20050171590A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/098,327 US20050171590A1 (en) 1998-11-04 2005-04-04 Cardiomyopathy treatment device with electrode therapy
US12/767,302 US20100222636A1 (en) 1998-11-04 2010-04-26 Cardiomyopathy treatment device with electrode therapy

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10696098P 1998-11-04 1998-11-04
US09/431,605 US6587734B2 (en) 1998-11-04 1999-11-01 Cardio therapeutic heart sack
US09/881,583 US6876887B2 (en) 1998-11-04 2001-06-13 Cardio therapeutic heart sack
US11/098,327 US20050171590A1 (en) 1998-11-04 2005-04-04 Cardiomyopathy treatment device with electrode therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/881,583 Continuation US6876887B2 (en) 1998-11-04 2001-06-13 Cardio therapeutic heart sack

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/767,302 Continuation US20100222636A1 (en) 1998-11-04 2010-04-26 Cardiomyopathy treatment device with electrode therapy

Publications (1)

Publication Number Publication Date
US20050171590A1 true US20050171590A1 (en) 2005-08-04

Family

ID=26804229

Family Applications (4)

Application Number Title Priority Date Filing Date
US09/431,605 Expired - Lifetime US6587734B2 (en) 1998-11-04 1999-11-01 Cardio therapeutic heart sack
US09/881,583 Expired - Lifetime US6876887B2 (en) 1998-11-04 2001-06-13 Cardio therapeutic heart sack
US11/098,327 Abandoned US20050171590A1 (en) 1998-11-04 2005-04-04 Cardiomyopathy treatment device with electrode therapy
US12/767,302 Abandoned US20100222636A1 (en) 1998-11-04 2010-04-26 Cardiomyopathy treatment device with electrode therapy

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/431,605 Expired - Lifetime US6587734B2 (en) 1998-11-04 1999-11-01 Cardio therapeutic heart sack
US09/881,583 Expired - Lifetime US6876887B2 (en) 1998-11-04 2001-06-13 Cardio therapeutic heart sack

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/767,302 Abandoned US20100222636A1 (en) 1998-11-04 2010-04-26 Cardiomyopathy treatment device with electrode therapy

Country Status (1)

Country Link
US (4) US6587734B2 (en)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6183411B1 (en) 1998-09-21 2001-02-06 Myocor, Inc. External stress reduction device and method
US6050936A (en) 1997-01-02 2000-04-18 Myocor, Inc. Heart wall tension reduction apparatus
US7883539B2 (en) 1997-01-02 2011-02-08 Edwards Lifesciences Llc Heart wall tension reduction apparatus and method
US8409846B2 (en) 1997-09-23 2013-04-02 The United States Of America As Represented By The Department Of Veteran Affairs Compositions, methods and devices for maintaining an organ
US6332893B1 (en) 1997-12-17 2001-12-25 Myocor, Inc. Valve to myocardium tension members device and method
US6260552B1 (en) 1998-07-29 2001-07-17 Myocor, Inc. Transventricular implant tools and devices
US6587734B2 (en) * 1998-11-04 2003-07-01 Acorn Cardiovascular, Inc. Cardio therapeutic heart sack
DE60007257T2 (en) * 1999-10-21 2004-09-16 Pohang University Of Science And Technology Foundation, Pohang Process for the preparation of cucurbituril derivatives
WO2001067985A1 (en) * 2000-03-10 2001-09-20 Paracor Surgical, Inc. Expandable cardiac harness for treating congestive heart failure
US6425856B1 (en) 2000-05-10 2002-07-30 Acorn Cardiovascular, Inc. Cardiac disease treatment and device
US6482146B1 (en) * 2000-06-13 2002-11-19 Acorn Cardiovascular, Inc. Cardiac disease treatment and device
US6951534B2 (en) * 2000-06-13 2005-10-04 Acorn Cardiovascular, Inc. Cardiac support device
US6723038B1 (en) 2000-10-06 2004-04-20 Myocor, Inc. Methods and devices for improving mitral valve function
JP4002720B2 (en) * 2000-11-22 2007-11-07 独立行政法人科学技術振興機構 Single cell long-term culture microscope
DK1423066T3 (en) 2001-09-07 2008-11-17 Mardil Inc Method and apparatus for external cardiac stabilization
EP1424958A2 (en) * 2001-09-10 2004-06-09 Paracor Medical, Inc. Cardiac harness
US7276021B2 (en) * 2001-10-31 2007-10-02 Paracor Medical, Inc. Heart failure treatment device and method
US7022063B2 (en) 2002-01-07 2006-04-04 Paracor Medical, Inc. Cardiac harness
US6764510B2 (en) 2002-01-09 2004-07-20 Myocor, Inc. Devices and methods for heart valve treatment
US20030229260A1 (en) * 2002-06-05 2003-12-11 Acorn Cardiovascular, Inc. Cardiac support device with tension indicator
US20030229261A1 (en) * 2002-06-06 2003-12-11 Acorn Cardiovascular, Inc. Cardiac support devices and methods of producing same
US7485089B2 (en) * 2002-09-05 2009-02-03 Paracor Medical, Inc. Cardiac harness
US20040230090A1 (en) * 2002-10-07 2004-11-18 Hegde Anant V. Vascular assist device and methods
US20040147803A1 (en) * 2002-10-07 2004-07-29 Hegde Anant V. Vascular assist device and methods
US7112219B2 (en) 2002-11-12 2006-09-26 Myocor, Inc. Devices and methods for heart valve treatment
US20070255093A1 (en) * 2002-11-15 2007-11-01 Lilip Lau Cardiac harness delivery device and method
US20050059855A1 (en) * 2002-11-15 2005-03-17 Lilip Lau Cardiac harness delivery device and method
US7736299B2 (en) 2002-11-15 2010-06-15 Paracor Medical, Inc. Introducer for a cardiac harness delivery
US7189203B2 (en) * 2002-11-15 2007-03-13 Paracor Medical, Inc. Cardiac harness delivery device and method
US20040249242A1 (en) * 2003-03-28 2004-12-09 Lilip Lau Multi-panel cardiac harness
US20050283042A1 (en) * 2003-03-28 2005-12-22 Steve Meyer Cardiac harness having radiopaque coating and method of use
CA2530429A1 (en) * 2003-07-10 2005-01-27 Paracor Medical, Inc. Self-anchoring cardiac harness
US7158839B2 (en) * 2003-11-07 2007-01-02 Paracor Medical, Inc. Cardiac harness for treating heart disease
US20070055091A1 (en) * 2004-12-02 2007-03-08 Lilip Lau Cardiac harness for treating congestive heart failure and for defibrillating and/or pacing/sensing
US20070106336A1 (en) * 2003-11-07 2007-05-10 Alan Schaer Cardiac harness assembly for treating congestive heart failure and for pacing/sensing
US7155295B2 (en) * 2003-11-07 2006-12-26 Paracor Medical, Inc. Cardiac harness for treating congestive heart failure and for defibrillating and/or pacing/sensing
US20060009831A1 (en) * 2003-11-07 2006-01-12 Lilip Lau Cardiac harness having leadless electrodes for pacing and sensing therapy
US20070106359A1 (en) * 2003-11-07 2007-05-10 Alan Schaer Cardiac harness assembly for treating congestive heart failure and for pacing/sensing
US7282024B2 (en) * 2004-01-12 2007-10-16 Paracor Medical, Inc. Cardiac harness having interconnected strands
US7285087B2 (en) * 2004-07-15 2007-10-23 Micardia Corporation Shape memory devices and methods for reshaping heart anatomy
US7402134B2 (en) * 2004-07-15 2008-07-22 Micardia Corporation Magnetic devices and methods for reshaping heart anatomy
JP2008510590A (en) * 2004-08-25 2008-04-10 パヴァド・メディカル・インコーポレーテッド Artificial sphincter
US8304181B2 (en) 2004-10-07 2012-11-06 Transmedics, Inc. Method for ex-vivo organ care and for using lactate as an indication of donor organ status
US9301519B2 (en) 2004-10-07 2016-04-05 Transmedics, Inc. Systems and methods for ex-vivo organ care
NZ614472A (en) 2004-10-07 2015-03-27 Transmedics Inc Systems and methods for ex-vivo organ care
US20060129026A1 (en) * 2004-12-15 2006-06-15 Joshua Wallin Apparatus and method for mounting a cardiac harness on the heart
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US7981065B2 (en) * 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US20060189840A1 (en) * 2005-02-18 2006-08-24 Acorn Cardiovascular, Inc. Transmyocardial delivery of cardiac wall tension relief
US9078428B2 (en) 2005-06-28 2015-07-14 Transmedics, Inc. Systems, methods, compositions and solutions for perfusing an organ
US20070032696A1 (en) * 2005-07-22 2007-02-08 Sieu Duong Cardiac harness delivery device
US7587247B2 (en) * 2005-08-01 2009-09-08 Paracor Medical, Inc. Cardiac harness having an optimal impedance range
US20070043416A1 (en) * 2005-08-19 2007-02-22 Cardiac Pacemakers, Inc. Implantable electrode array
US20070073218A1 (en) * 2005-09-26 2007-03-29 Lilip Lau Inflatable cardiac device for treating and preventing ventricular remodeling
US20070208217A1 (en) 2006-03-03 2007-09-06 Acorn Cardiovascular, Inc. Self-adjusting attachment structure for a cardiac support device
CA2881613C (en) 2006-04-19 2017-11-14 Stanley Kyi Systems and methods for ex vivo organ care
US20070270882A1 (en) 2006-05-19 2007-11-22 Acorn Cardiovascular, Inc. Pericardium management method for intra-pericardial surgical procedures
US20070287883A1 (en) * 2006-06-07 2007-12-13 Lilip Lau Apparatus and method for pulling a cardiac harness onto a heart
US20080097146A1 (en) 2006-06-29 2008-04-24 Acorn Cardiovascular, Inc. Cardiac support device with low friction delivery structures
US7877142B2 (en) * 2006-07-05 2011-01-25 Micardia Corporation Methods and systems for cardiac remodeling via resynchronization
US7651462B2 (en) 2006-07-17 2010-01-26 Acorn Cardiovascular, Inc. Cardiac support device delivery tool with release mechanism
US20080091057A1 (en) * 2006-10-11 2008-04-17 Cardiac Pacemakers, Inc. Method and apparatus for passive left atrial support
US9457179B2 (en) * 2007-03-20 2016-10-04 Transmedics, Inc. Systems for monitoring and applying electrical currents in an organ perfusion system
US20090048480A1 (en) * 2007-08-13 2009-02-19 Paracor Medical, Inc. Cardiac harness delivery device
US8192351B2 (en) 2007-08-13 2012-06-05 Paracor Medical, Inc. Medical device delivery system having integrated introducer
US8092363B2 (en) 2007-09-05 2012-01-10 Mardil, Inc. Heart band with fillable chambers to modify heart valve function
US9814230B2 (en) 2008-01-31 2017-11-14 Transmedics, Inc. Systems and methods for ex vivo lung care
US20090259093A1 (en) * 2008-04-14 2009-10-15 Bhat Nikhil D Artificial sphincter with piezoelectric actuator
US20120188042A1 (en) * 2010-08-20 2012-07-26 Claude Timothy J Implantable medical device electrical lead body
WO2012111832A1 (en) 2011-02-17 2012-08-23 矢崎総業株式会社 Shield sleeve
AU2012242578B2 (en) 2011-04-14 2016-07-21 Transmedics, Inc. Organ care solution for ex-vivo machine perfusion of donor lungs
WO2014059433A2 (en) 2012-10-12 2014-04-17 Mardil, Inc. Cardiac treatment system and method
EP2983731A4 (en) * 2013-04-12 2017-01-18 William Marsh Rice University Strong, conductive carbon nanotube electrodes
USD717954S1 (en) 2013-10-14 2014-11-18 Mardil, Inc. Heart treatment device
CN113287600B (en) 2014-06-02 2022-08-19 特兰斯迈迪茨公司 Perfusion circuit and system for perfusion of isolated liver and system for preservation thereof
CN112933394B (en) 2015-09-09 2023-10-24 特兰斯迈迪茨公司 Aortic cannula for use in an ex vivo organ care system
EP3984568A1 (en) 2016-07-14 2022-04-20 Hollister Incorporated Hygienic medical devices having hydrophilic coatings and methods of forming the same

Citations (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3587567A (en) * 1968-12-20 1971-06-28 Peter Paul Schiff Mechanical ventricular assistance assembly
US3983863A (en) * 1975-06-02 1976-10-05 American Hospital Supply Corporation Heart support for coronary artery surgery
US4048990A (en) * 1976-09-17 1977-09-20 Goetz Robert H Heart massage apparatus
US4403604A (en) * 1982-05-13 1983-09-13 Wilkinson Lawrence H Gastric pouch
US4428375A (en) * 1982-02-16 1984-01-31 Ellman Barry R Surgical bag for splenorrhaphy
US4630597A (en) * 1984-04-30 1986-12-23 Adrian Kantrowitz Dynamic aortic patch for thoracic or abdominal implantation
US4690134A (en) * 1985-07-01 1987-09-01 Snyders Robert V Ventricular assist device
US4821723A (en) * 1987-02-27 1989-04-18 Intermedics Inc. Biphasic waveforms for defibrillation
US4827932A (en) * 1987-02-27 1989-05-09 Intermedics Inc. Implantable defibrillation electrodes
US4878890A (en) * 1986-10-15 1989-11-07 Ethicon, Inc. Perihepatic prosthesis
US4936857A (en) * 1987-02-23 1990-06-26 Kulik Yaroslav P Prosthetic pericardium
US4957477A (en) * 1986-05-22 1990-09-18 Astra Tech Ab Heart assist jacket and method of using it
US4973300A (en) * 1989-09-22 1990-11-27 Pioneering Technologies, Inc. Cardiac sling for circumflex coronary artery surgery
US4976730A (en) * 1988-10-11 1990-12-11 Kwan Gett Clifford S Artificial pericardium
US5057117A (en) * 1989-04-27 1991-10-15 The Research Foundation Of State University Of New York Method and apparatus for hemostasis and compartmentalization of a bleeding internal bodily organ
US5087243A (en) * 1990-06-18 1992-02-11 Boaz Avitall Myocardial iontophoresis
US5131905A (en) * 1990-07-16 1992-07-21 Grooters Ronald K External cardiac assist device
US5150706A (en) * 1991-08-15 1992-09-29 Cox James L Cooling net for cardiac or transplant surgery
US5186711A (en) * 1989-03-07 1993-02-16 Albert Einstein College Of Medicine Of Yeshiva University Hemostasis apparatus and method
US5192314A (en) * 1991-12-12 1993-03-09 Daskalakis Michael K Synthetic intraventricular implants and method of inserting
US5256132A (en) * 1992-08-17 1993-10-26 Snyders Robert V Cardiac assist envelope for endoscopic application
US5290217A (en) * 1991-10-10 1994-03-01 Earl K. Sipes Method and apparatus for hernia repair
US5336253A (en) * 1993-02-23 1994-08-09 Medtronic, Inc. Pacing and cardioversion lead systems with shared lead conductors
US5356432A (en) * 1993-02-05 1994-10-18 C. R. Bard, Inc. Implantable mesh prosthesis and method for repairing muscle or tissue wall defects
US5383840A (en) * 1992-07-28 1995-01-24 Vascor, Inc. Biocompatible ventricular assist and arrhythmia control device including cardiac compression band-stay-pad assembly
US5385156A (en) * 1993-08-27 1995-01-31 Rose Health Care Systems Diagnostic and treatment method for cardiac rupture and apparatus for performing the same
US5429584A (en) * 1990-11-09 1995-07-04 Mcgill University Cardiac assist method and apparatus
US5507779A (en) * 1994-04-12 1996-04-16 Ventritex, Inc. Cardiac insulation for defibrillation
US5524633A (en) * 1991-11-25 1996-06-11 Advanced Surgical, Inc. Self-deploying isolation bag
US5533958A (en) * 1993-06-17 1996-07-09 Wilk; Peter J. Intrapericardial assist device and associated method
US5603337A (en) * 1994-12-05 1997-02-18 Jarvik; Robert Two-stage cardiomyoplasty
US5647380A (en) * 1995-06-07 1997-07-15 W. L. Gore & Associates, Inc. Method of making a left ventricular assist device
US5702343A (en) * 1996-10-02 1997-12-30 Acorn Medical, Inc. Cardiac reinforcement device
US5713954A (en) * 1995-06-13 1998-02-03 Abiomed R&D, Inc. Extra cardiac ventricular assist device
US5800528A (en) * 1995-06-13 1998-09-01 Abiomed R & D, Inc. Passive girdle for heart ventricle for therapeutic aid to patients having ventricular dilatation
US5800334A (en) * 1993-06-17 1998-09-01 Wilk; Peter J. Intrapericardial assist device and associated method
US5824028A (en) * 1996-09-20 1998-10-20 The Uab Research Foundation Line electrode oriented relative to fiber direction
US5971910A (en) * 1996-10-18 1999-10-26 Cardio Technologies, Inc. Method and apparatus for assisting a heart to pump blood by applying substantially uniform pressure to the ventricles
US6076013A (en) * 1999-01-14 2000-06-13 Brennan; Edward F. Apparatus and methods for treating congestive heart failure
US6077214A (en) * 1998-07-29 2000-06-20 Myocor, Inc. Stress reduction apparatus and method
US6085754A (en) * 1998-07-13 2000-07-11 Acorn Cardiovascular, Inc. Cardiac disease treatment method
US6110100A (en) * 1998-04-22 2000-08-29 Scimed Life Systems, Inc. System for stress relieving the heart muscle and for controlling heart function
US6123662A (en) * 1998-07-13 2000-09-26 Acorn Cardiovascular, Inc. Cardiac disease treatment and device
US6169922B1 (en) * 1998-11-18 2001-01-02 Acorn Cardiovascular, Inc. Defibrillating cardiac jacket with interwoven electrode grids
US6564094B2 (en) * 2000-12-22 2003-05-13 Acorn Cardiovascular, Inc. Cardiac disease treatment and device
US6587734B2 (en) * 1998-11-04 2003-07-01 Acorn Cardiovascular, Inc. Cardio therapeutic heart sack

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1009457A1 (en) 1981-07-15 1983-04-07 Проблемная Лаборатория "Вспомогательного Кровообращения" Благовещенского Медицинского Института Artificial pericardium
JPS60203250A (en) 1984-03-29 1985-10-14 日本ゼオン株式会社 Patch for heart operation
US4834707A (en) 1987-09-16 1989-05-30 Evans Phillip H Venting apparatus and method for cardiovascular pumping application
DE29517393U1 (en) 1995-11-03 1996-02-01 Hohmann Claas Dr Med Pericardial prosthesis
US6050936A (en) 1997-01-02 2000-04-18 Myocor, Inc. Heart wall tension reduction apparatus
DE59811956D1 (en) 1997-06-21 2004-10-21 Acorn Cardiovascular Inc BAG FOR AT LEAST PARTIAL ENCLOSURE OF A HEART

Patent Citations (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3587567A (en) * 1968-12-20 1971-06-28 Peter Paul Schiff Mechanical ventricular assistance assembly
US3983863A (en) * 1975-06-02 1976-10-05 American Hospital Supply Corporation Heart support for coronary artery surgery
US4048990A (en) * 1976-09-17 1977-09-20 Goetz Robert H Heart massage apparatus
US4428375A (en) * 1982-02-16 1984-01-31 Ellman Barry R Surgical bag for splenorrhaphy
US4403604A (en) * 1982-05-13 1983-09-13 Wilkinson Lawrence H Gastric pouch
US4630597A (en) * 1984-04-30 1986-12-23 Adrian Kantrowitz Dynamic aortic patch for thoracic or abdominal implantation
US4690134A (en) * 1985-07-01 1987-09-01 Snyders Robert V Ventricular assist device
US4957477A (en) * 1986-05-22 1990-09-18 Astra Tech Ab Heart assist jacket and method of using it
US4878890A (en) * 1986-10-15 1989-11-07 Ethicon, Inc. Perihepatic prosthesis
US4936857A (en) * 1987-02-23 1990-06-26 Kulik Yaroslav P Prosthetic pericardium
US4821723A (en) * 1987-02-27 1989-04-18 Intermedics Inc. Biphasic waveforms for defibrillation
US4827932A (en) * 1987-02-27 1989-05-09 Intermedics Inc. Implantable defibrillation electrodes
US4976730A (en) * 1988-10-11 1990-12-11 Kwan Gett Clifford S Artificial pericardium
US5186711A (en) * 1989-03-07 1993-02-16 Albert Einstein College Of Medicine Of Yeshiva University Hemostasis apparatus and method
US5057117A (en) * 1989-04-27 1991-10-15 The Research Foundation Of State University Of New York Method and apparatus for hemostasis and compartmentalization of a bleeding internal bodily organ
US4973300A (en) * 1989-09-22 1990-11-27 Pioneering Technologies, Inc. Cardiac sling for circumflex coronary artery surgery
US5087243A (en) * 1990-06-18 1992-02-11 Boaz Avitall Myocardial iontophoresis
US5131905A (en) * 1990-07-16 1992-07-21 Grooters Ronald K External cardiac assist device
US5429584A (en) * 1990-11-09 1995-07-04 Mcgill University Cardiac assist method and apparatus
US5150706A (en) * 1991-08-15 1992-09-29 Cox James L Cooling net for cardiac or transplant surgery
US5290217A (en) * 1991-10-10 1994-03-01 Earl K. Sipes Method and apparatus for hernia repair
US5524633A (en) * 1991-11-25 1996-06-11 Advanced Surgical, Inc. Self-deploying isolation bag
US5192314A (en) * 1991-12-12 1993-03-09 Daskalakis Michael K Synthetic intraventricular implants and method of inserting
US5558617A (en) * 1992-07-28 1996-09-24 Vascor, Inc. Cardiac compression band-stay-pad assembly and method of replacing the same
US5383840A (en) * 1992-07-28 1995-01-24 Vascor, Inc. Biocompatible ventricular assist and arrhythmia control device including cardiac compression band-stay-pad assembly
US5256132A (en) * 1992-08-17 1993-10-26 Snyders Robert V Cardiac assist envelope for endoscopic application
US5356432A (en) * 1993-02-05 1994-10-18 C. R. Bard, Inc. Implantable mesh prosthesis and method for repairing muscle or tissue wall defects
US5356432B1 (en) * 1993-02-05 1997-02-04 Bard Inc C R Implantable mesh prosthesis and method for repairing muscle or tissue wall defects
US5336253A (en) * 1993-02-23 1994-08-09 Medtronic, Inc. Pacing and cardioversion lead systems with shared lead conductors
US5800334A (en) * 1993-06-17 1998-09-01 Wilk; Peter J. Intrapericardial assist device and associated method
US5533958A (en) * 1993-06-17 1996-07-09 Wilk; Peter J. Intrapericardial assist device and associated method
US5385156A (en) * 1993-08-27 1995-01-31 Rose Health Care Systems Diagnostic and treatment method for cardiac rupture and apparatus for performing the same
US5507779A (en) * 1994-04-12 1996-04-16 Ventritex, Inc. Cardiac insulation for defibrillation
US5603337A (en) * 1994-12-05 1997-02-18 Jarvik; Robert Two-stage cardiomyoplasty
US5647380A (en) * 1995-06-07 1997-07-15 W. L. Gore & Associates, Inc. Method of making a left ventricular assist device
US6224540B1 (en) * 1995-06-13 2001-05-01 Abiomed, Inc. Passive girdle for heart ventricle for therapeutic aid to patients having ventricular dilatation
US5713954A (en) * 1995-06-13 1998-02-03 Abiomed R&D, Inc. Extra cardiac ventricular assist device
US5800528A (en) * 1995-06-13 1998-09-01 Abiomed R & D, Inc. Passive girdle for heart ventricle for therapeutic aid to patients having ventricular dilatation
US5824028A (en) * 1996-09-20 1998-10-20 The Uab Research Foundation Line electrode oriented relative to fiber direction
US5702343A (en) * 1996-10-02 1997-12-30 Acorn Medical, Inc. Cardiac reinforcement device
US6077218A (en) * 1996-10-02 2000-06-20 Acorn Cardiovascular, Inc. Cardiac reinforcement device
US5971910A (en) * 1996-10-18 1999-10-26 Cardio Technologies, Inc. Method and apparatus for assisting a heart to pump blood by applying substantially uniform pressure to the ventricles
US6494825B1 (en) * 1998-04-22 2002-12-17 Scimed Life Systems, Inc. System for stress relieving the heart muscle and for controlling heart function
US6110100A (en) * 1998-04-22 2000-08-29 Scimed Life Systems, Inc. System for stress relieving the heart muscle and for controlling heart function
US6085754A (en) * 1998-07-13 2000-07-11 Acorn Cardiovascular, Inc. Cardiac disease treatment method
US6123662A (en) * 1998-07-13 2000-09-26 Acorn Cardiovascular, Inc. Cardiac disease treatment and device
US6077214A (en) * 1998-07-29 2000-06-20 Myocor, Inc. Stress reduction apparatus and method
US6587734B2 (en) * 1998-11-04 2003-07-01 Acorn Cardiovascular, Inc. Cardio therapeutic heart sack
US6876887B2 (en) * 1998-11-04 2005-04-05 Acorn Cardiovascular, Inc. Cardio therapeutic heart sack
US6169922B1 (en) * 1998-11-18 2001-01-02 Acorn Cardiovascular, Inc. Defibrillating cardiac jacket with interwoven electrode grids
US6076013A (en) * 1999-01-14 2000-06-13 Brennan; Edward F. Apparatus and methods for treating congestive heart failure
US6564094B2 (en) * 2000-12-22 2003-05-13 Acorn Cardiovascular, Inc. Cardiac disease treatment and device

Also Published As

Publication number Publication date
US20020151950A1 (en) 2002-10-17
US20100222636A1 (en) 2010-09-02
US6876887B2 (en) 2005-04-05
US20020173824A1 (en) 2002-11-21
US6587734B2 (en) 2003-07-01

Similar Documents

Publication Publication Date Title
US6587734B2 (en) Cardio therapeutic heart sack
AU637353B2 (en) Patch electrodes for use with defibrillators
US5411527A (en) Difibrillation electrodes and implantation
US7013182B1 (en) Conductive polymer sheath on defibrillator shocking coils
US5433730A (en) Conductive pouch electrode for defibrillation
JP3447737B2 (en) Electrophysiological lead for implants
US6408213B1 (en) Low profile, ventricular, transvenous, epicardial defibrillation lead
US5755762A (en) Medical lead and method of making and using
US10328272B2 (en) Retrievability for implantable medical devices
US5902329A (en) Explantable lead
US8224461B2 (en) Porous fiber electrode coating and related methods
JPH08505539A (en) Electrode for implant
EP3389735B1 (en) Biologically inert coating for implantable medical devices
CN103143114A (en) Detection/stimulation microprobe implantable in venous, arterial or lymphatic networks
US5375609A (en) Pacing lead insulator
Sonn et al. A prototype flexible microelectrode array for implant-prosthesis applications
US5419921A (en) Pacing lead insulator
JP2000510713A (en) Ion introduction material
CN109414525A (en) Functionalized PEG for implantable medical device
US9861814B2 (en) Medical electrical lead having biological surface and methods of making and using same
Hughes et al. A new polyurethane and process for pacer leads
TARJAN Implantable Electrodes and Leads

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION